IRTC logo

iRhythm Technologies, Inc. Stock Price

NasdaqGS:IRTC Community·US$5.9b Market Cap
  • 1 Narratives written by author
  • 0 Comments on narratives written by author
  • 8 Fair Values set on narratives written by author

IRTC Share Price Performance

US$182.74
94.84 (107.90%)
US$219.93
Fair Value
US$182.74
94.84 (107.90%)
16.9% undervalued intrinsic discount
US$219.93
Fair Value
Price US$182.74
AnalystConsensusTarget US$219.93

IRTC Community Narratives

AnalystConsensusTarget·
Fair Value US$219.93 16.9% undervalued intrinsic discount

IRTC: Future Performance Will Reflect Both Product Momentum And Regulatory Uncertainty

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative

Trending Discussion

Updated Narratives

IRTC logo

IRTC: Future Core Business Momentum Will Drive Stronger Market Share Gains

Fair Value: US$219.93 16.9% undervalued intrinsic discount
3 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Snowflake Analysis

Reasonable growth potential with mediocre balance sheet.

1 Risk
2 Rewards

iRhythm Technologies, Inc. Key Details

US$702.6m

Revenue

US$208.3m

Cost of Revenue

US$494.3m

Gross Profit

US$545.7m

Other Expenses

-US$51.5m

Earnings

Last Reported Earnings
Sep 30, 2025
Next Reporting Earnings
n/a
-1.60
70.35%
-7.32%
532.2%
View Full Analysis

About IRTC

Founded
2006
Employees
2000
CEO
Quentin Blackford
WebsiteView website
www.irhythmtech.com

iRhythm Technologies, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with Verily Life Sciences LLC and Verity Ireland Limited to develop various next-generation atrial fibrillation screening, detection, or monitoring products. iRhythm Technologies, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Recent IRTC News & Updates

Recent updates

No updates